Completed
CLEAR-2: Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality
- Status
- Completed
- Registry ID
- NCT03498313
- Type
- Interventional (tests a treatment)
- Phase
- Phase 4
- Conditions
- Suicidal Ideation
- What is tested
- Transdermal Estradiol + Placebo (drug); Oral Micronized Progesterone + Placebo (drug); Placebos (drug)
- Sponsor
- University of Illinois at Chicago
- Where
- United States
- Participants
- 60
- Start
- 2018-07-27
- Completion
- 2021-05-09
- Last update
- 2022-09-14
- Results posted
- Yes
About the study
This within-person, crossover, 3-condition, placebo-controlled study compares the impact of three perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The three conditions are (1) perimenstrual withdrawal from estradiol only (during progesterone stabilization), (2) perimenstrual withdrawal from progesterone only (during estradiol stabilization), and (3) perimenstrual withdrawal from both estradiol and progesterone during placebo.
Summary from ClinicalTrials.gov.